157 related articles for article (PubMed ID: 37184208)
1. Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.
Vittal A; Niewisch MR; Bhala S; Kudaravalli P; Rahman F; Hercun J; Kleiner DE; Savage SA; Koh C; Heller T; Giri N
Hepatology; 2023 Dec; 78(6):1777-1787. PubMed ID: 37184208
[TBL] [Abstract][Full Text] [Related]
2. Disease progression and clinical outcomes in telomere biology disorders.
Niewisch MR; Giri N; McReynolds LJ; Alsaggaf R; Bhala S; Alter BP; Savage SA
Blood; 2022 Mar; 139(12):1807-1819. PubMed ID: 34852175
[TBL] [Abstract][Full Text] [Related]
3. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.
Walne AJ; Vulliamy T; Beswick R; Kirwan M; Dokal I
Blood; 2008 Nov; 112(9):3594-600. PubMed ID: 18669893
[TBL] [Abstract][Full Text] [Related]
4. Telomere biology disorders may manifest as common variable immunodeficiency (CVID).
Rolles B; Caballero-Oteyza A; Proietti M; Goldacker S; Warnatz K; Camacho-Ordonez N; Prader S; Schmid JP; Vieri M; Isfort S; Meyer R; Kirschner M; Brümmendorf TH; Beier F; Grimbacher B
Clin Immunol; 2023 Dec; 257():109837. PubMed ID: 37944684
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders.
Balakumaran A; Mishra PJ; Pawelczyk E; Yoshizawa S; Sworder BJ; Cherman N; Kuznetsov SA; Bianco P; Giri N; Savage SA; Merlino G; Dumitriu B; Dunbar CE; Young NS; Alter BP; Robey PG
Blood; 2015 Jan; 125(5):793-802. PubMed ID: 25499762
[TBL] [Abstract][Full Text] [Related]
6. Dyskeratosis congenita: telomerase, telomeres and anticipation.
Marrone A; Walne A; Dokal I
Curr Opin Genet Dev; 2005 Jun; 15(3):249-57. PubMed ID: 15917199
[TBL] [Abstract][Full Text] [Related]
7. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders.
Ballew BJ; Savage SA
Expert Rev Hematol; 2013 Jun; 6(3):327-37. PubMed ID: 23782086
[TBL] [Abstract][Full Text] [Related]
8. Dyskeratosis congenita and telomere biology disorders.
Savage SA
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):637-648. PubMed ID: 36485133
[TBL] [Abstract][Full Text] [Related]
9. Editing TINF2 as a potential therapeutic approach to restore telomere length in dyskeratosis congenita.
Choo S; Lorbeer FK; Regalado SG; Short SB; Wu S; Rieser G; Bertuch AA; Hockemeyer D
Blood; 2022 Aug; 140(6):608-618. PubMed ID: 35421215
[TBL] [Abstract][Full Text] [Related]
10. [Dyskeratosis congenita: an update].
Mialou V; Leblanc T; Peffault de Latour R; Dalle JH; Socié G
Arch Pediatr; 2013 Mar; 20(3):299-306. PubMed ID: 23352883
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder.
Giri N; Ravichandran S; Wang Y; Gadalla SM; Alter BP; Fontana J; Savage SA
ERJ Open Res; 2019 Oct; 5(4):. PubMed ID: 31754622
[TBL] [Abstract][Full Text] [Related]
12. Dyskeratosis congenita: a disorder of defective telomere maintenance?
Walne AJ; Marrone A; Dokal I
Int J Hematol; 2005 Oct; 82(3):184-9. PubMed ID: 16207588
[TBL] [Abstract][Full Text] [Related]
13. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.
Niewisch MR; Savage SA
Expert Rev Hematol; 2019 Dec; 12(12):1037-1052. PubMed ID: 31478401
[No Abstract] [Full Text] [Related]
14. Dyskeratosis congenita.
Dokal I
Hematology Am Soc Hematol Educ Program; 2011; 2011():480-6. PubMed ID: 22160078
[TBL] [Abstract][Full Text] [Related]
15. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita.
Savage SA; Giri N; Baerlocher GM; Orr N; Lansdorp PM; Alter BP
Am J Hum Genet; 2008 Feb; 82(2):501-9. PubMed ID: 18252230
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of Liver Pathology in Dyskeratosis Congenita.
Putra J; Agarwal S; Al-Ibraheemi A; Alomari AI; Perez-Atayde AR
Am J Surg Pathol; 2023 Aug; 47(8):869-877. PubMed ID: 37246821
[TBL] [Abstract][Full Text] [Related]
17. Robust DNA Damage Response and Elevated Reactive Oxygen Species in TINF2-Mutated Dyskeratosis Congenita Cells.
Pereboeva L; Hubbard M; Goldman FD; Westin ER
PLoS One; 2016; 11(2):e0148793. PubMed ID: 26859482
[TBL] [Abstract][Full Text] [Related]
18. Treatment of dyskeratosis congenita-associated pulmonary fibrosis with danazol.
Zlateska B; Ciccolini A; Dror Y
Pediatr Pulmonol; 2015 Dec; 50(12):E48-51. PubMed ID: 26083318
[TBL] [Abstract][Full Text] [Related]
19. Dyskeratosis congenita associated with leukoplakia of the tongue.
Noto Z; Tomihara K; Furukawa K; Noguchi M
Int J Oral Maxillofac Surg; 2016 Jun; 45(6):760-3. PubMed ID: 26778687
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
